Avid Bioservices, Inc.

Good day, ladies and gentlemen, and welcome to the AVID Fire Services Third Quarter Fiscal 2022 Financial Results Conference Call. At this time, all participants are on a listen-only mode. Later, we will conduct a question-and-answer session, and instructors will file that time. As a reminder, this conference call may be recorded. I would now like to hand the conference over to Tim Browns of AVID's Investor Relations Group. Please go ahead.

Thank you. Good afternoon, and thank you for joining us. On today's call, we have Nick Green, President and CEO, Dan Hart, Chief Financial Officer, and Matt Quitniak, AVID's Chief Commercial Officer. Today, we will be providing an overview of AVID Bioservices contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended January 31st, 2022. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, March 8th, 2022, will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the current belief of the company, which involves a number of assumptions, risks, and uncertainties. Actual results could differ from these statements, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release including relevant non-GAAP reconciliations on our corporate website at avidbio.com. With that, I will turn the call over to Nick Green, AVID's President and CEO.

Nick Green, AVID's President and CEO Thank you, Tim. And thank you to everyone who has dialed in, and to those who are participating today via webcast. We are very pleased with the achievements of the third quarter. During the period, we again recorded year-over-year growth in revenues, gross margin, net income, backlog, and adjusted EBITDA. Our business development team had an exceptional quarter, signing multiple new orders that will span the range of Avid's current capabilities. With respect to our expansions, we continue to make excellent progress on our new mammalian capacity in our Myford facility, as well as with our viral vector facility in Costa Mesa, California. Matt and I will provide additional details on business development and operations for the period, following an overview of our third quarter financial results. And for that, I'll turn the call over to Dan.